Compare NTAP & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTAP | BIIB |
|---|---|---|
| Founded | 1992 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.3B | 27.3B |
| IPO Year | 1996 | 1996 |
| Metric | NTAP | BIIB |
|---|---|---|
| Price | $165.63 | $207.44 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 25 |
| Target Price | $116.58 | ★ $206.83 |
| AVG Volume (30 Days) | ★ 2.7M | 1.1M |
| Earning Date | 05-28-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ 11.99 | N/A |
| EPS | ★ 6.35 | 2.15 |
| Revenue | $6,237,000,000.00 | ★ $9,890,600,000.00 |
| Revenue This Year | $6.22 | N/A |
| Revenue Next Year | $4.91 | N/A |
| P/E Ratio | ★ $25.78 | $96.94 |
| Revenue Growth | ★ 5.59 | 2.22 |
| 52 Week Low | $93.69 | $121.06 |
| 52 Week High | $192.83 | $219.72 |
| Indicator | NTAP | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 63.08 | 54.34 |
| Support Level | $95.25 | $170.52 |
| Resistance Level | $192.83 | $219.72 |
| Average True Range (ATR) | 6.46 | 6.91 |
| MACD | -0.95 | 0.42 |
| Stochastic Oscillator | 86.58 | 51.63 |
NetApp Inc is storage hardware provider into a software-driven, cloud-centric data infrastructure company. Its flagship ONTAP data management software, together with a comprehensive portfolio of all-flash, hybrid-flash, and cloud-native solutions, forms the backbone of digital transformation for thousands of enterprises world'wide. Its operations are organized into two segments Hybrid Cloud and Public Cloud. It generates majority of revenue from Hybrid Cloud offers a unified data storage portfolio of storage management and infrastructure solutions that helps customers modernize their data centers. Hybrid Cloud includes software, hardware, and related support, along with professional and other services. It generates majority of revenue from United States followed by International market.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).